• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of xcience and technology policy >3 The Story of Drug-Eluting Coronary Stents
【24h】

3 The Story of Drug-Eluting Coronary Stents

机译：3药物洗脱冠状动脉支架的故事

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Our detailed example of a biomedical innovation that received significant public funding throughout its history is the story of the drug-eluting coronary stent that was invented in a research laboratory at NIA within NIH and subsequently commercialized for use in interventional cardiology in the worldwide coronary stent market. The technology earned millions of dollars in royalties for the U.S. government. Those royalties repaid many times over the public's investment in the NIA research that created the invention, and more importantly, the technology, when successfully transferred as the commercialized Taxol (paclitaxel—Taxol is the brand name for the drug paclitaxel) coated coronary stents used in interventional cardiology, allowed millions of patients to avoid coronary artery bypass surgery.
机译：我们详细的一个生物医学创新的例子接受重大的公共资金在整个历史的故事发明的药物洗脱冠状动脉支架NIA在国家卫生研究院和研究实验室随后商业化使用介入心脏病学的冠状动脉支架市场。美国数百万美元的版税政府。NIA在公众的投资研究发明创造,更重要的是,技术,成功地转移商业化紫杉醇(paclitaxel-Taxol是品牌药物紫杉醇)涂层冠状动脉支架用于介入心脏病学,使得数以百万计的患者避免冠状动脉搭桥手术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号